Navigation Links
Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income
Date:2/8/2012

LAKEWOOD, Colo., Feb. 8, 2012 /PRNewswire/ -- Mesa Laboratories, Inc. (NASDAQ: MLAB) today reported a 21 percent increase in revenue and a 58 percent increase in GAAP net income for the fiscal third quarter ended December 31, 2011.

Highlights:

  • Quarterly GAAP net income increased 58% year over year to $1,987 ,000
  • Quarterly revenues increased 21% year over year to $9,259,000
  • Achieved 13% organic year over year sales growth in the fiscal third quarter
  • Quarterly non-GAAP diluted earnings per share increased to $0.63 (1)
  • Nine-month non-GAAP diluted earnings per share increased to $1.86(1)

  • For the third quarter of fiscal 2012, net sales increased 21 percent to $9,259,000 from $7,652,000 in the same quarter last year. GAAP net income for the quarter increased 58 percent to $1,987,000, or $0.57 per diluted share, compared to $1,258,000, or $0.37 per diluted share one year ago.

    For the first nine months of fiscal 2012, net sales increased 20 percent to $27,438,000 from $22,861,000 in the same period last year. Net income for the first nine months increased 43 percent to $5,720,000, or $1.66 per diluted share, compared to $4,006,000, or $1.21 per share one year ago.

    On a non-GAAP basis, adjusted net income for the third quarter of fiscal 2012 increased 53 percent to $2,217,000, or $0.63 per diluted share of common stock, compared to $1,446,000, or $0.43 per diluted share of common stock last year. For the first nine months of fiscal 2012, adjusted net income increased 42 percent to $6,427,000, or $1.86 per diluted share of common stock, compared to $4,515,000, or $1.36 per diluted share of common stock during the same period last year. See the note below for an explanation of the calculation of adjusted net income and adjusted net income per share.

    "Mesa posted another quarter of excellent financial performance," said John J. Sullivan, President and Chief Executive Officer. "It is hard to single out any one factor that was responsible for our revenue growth and increased profitability.  However, I am especially pleased that Mesa posted its second consecutive quarter of 13% organic growth.  Coupling this organic growth with the increased revenue from the Apex acquisition drove our revenue and profitability up significantly.  I am also pleased that our profit margins are holding up very well, near Mesa's long term averages.  This quarter, our gross margins reached 64%, while operating income and net income were a healthy 34% and 21%, respectively.  All of these profitability measures were significantly above the third quarter last fiscal year.  We expected to see improved profitability this year, due to the addition of the Apex products, increased production efficiency, and elimination of certain acquisition expenses, and I applaud the entire Mesa team for helping make this expectation become a reality."

    "Going forward, we have good momentum entering our important fourth quarter and we expect that we will be able to report increased sales and profits," continued John Sullivan.  "Mesa's fourth quarter last fiscal year was unusually strong and our growth, on a percentage basis, will likely be somewhat lower than our previous three quarters.  Also, this will be the first full quarter in which there is a direct comparison for the Apex business.  Nevertheless, we expect to finish strong and report record revenue and profits for the full fiscal year."

    The Company's instrumentation product sales and service revenues increased 18 percent during the third quarter and 12 percent during the first nine month period of fiscal 2012, compared to the prior year periods. The revenue increase in the third quarter was due primarily to organic growth of the DataTrace products, while the revenue increase in the nine month period was due to increased sales of DataTrace and Medical products.

    Sales of the Company's Biological Indicator products increased 25 percent during the third quarter and 29 percent during the first nine month period of fiscal 2012, compared to the same periods last year. The increase in Biological Indicator sales during the quarter and nine month period was due to 9 percent and 13 percent organic growth, respectively, plus the revenue added as a result of the acquisition of the Apex products in December, 2010.

    Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

    This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form 10-K for the year ended March 31, 2011 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.

    (1) The non-GAAP measures of adjusted net income and adjusted earnings per share are defined to exclude the impacts of non-cash intangibles amortization, net of its tax effects. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.Financial SummaryStatements of Earnings(Unaudited)(Amounts in thousands except EPS)

    Three months ended
    December 31,Nine Months ended
    December 31,2011201020112010Revenues

    $9,259

    $7,652

    $27,438

    $22,861Cost of revenues

    3,374

    3,212

    10,391

    9,488  Gross profit

    5,885

    4,440

    17,047

    13,373Operating expense

    2,723

    2,438

    7,906

    6,835  Operating income

    3,162

    2,002

    9,141

    6,538Other expense & (income)

    31

    33

    130

    79  Earnings before taxes

    3,131

    1,969

    9,011

    6,459Income taxes

    1,144

    711

    3,291

    2,453  Net income

    $1,987

    $1,258

    $5,720

    $4,006EPS (basic)

    $0.60

    $0.39

    $1.74

    $1.24EPS (diluted)

    $0.57

    $0.37

    $1.66

    $1.21Average shares (basic)

    3,286

    3,234

    3,280

    3,226Average shares (diluted)

    3,498

    3,355

    3,454

    3,316Balance Sheets(Amounts in thousands)

    December 31,
    2011(Unaudited)

    March 31,
    2011Cash and cash equivalents

    $5,691

    $3,546Other current assets

    11,773

    13,716  Total current assets

    17,464

    17,262Property and equipment

    7,342

    7,308Other assets

    25,416

    26,414  Total assets

    $50,222

    $50,984Liabilities

    $8,516

    $14,567Stockholders' equity

    41,706

    36,417  Total liabilities and stockholders' equity

    $50,222

    $50,984Reconciliation of Non-GAAP Measures(Amounts in thousands except EPS)

    Three months ended
    December 31,Nine Months ended
    December 31,2011201020112010Net income

    $1,987

    $1,258

    $5,720

    $4,006Intangible amortization,

     net of taxes

    230

    188

    707

    509Adjusted net income

    $2,217

    $1,446

    $6,427

    $4,515Adjusted EPS (diluted)

    $0.63

    $0.43

    $1.86

    $1.36Average shares (diluted)

    3,498

    3,355

    3,454

    3,316The non-GAAP measures of adjusted net income and adjusted earnings per share presented in the reconciliation above are defined to exclude the impacts of non-cash intangibles amortization, net of their tax effects. The tax effect is calculated using the average corporate rate for that period multiplied by the elimination. We believe that excluding these acquisition related expenses provides the ability to understand the benefits of acquisitions based on their cash return.

    We provide non-GAAP net income and non-GAAP earnings per share amounts in order to provide meaningful supplemental information regarding our operational performance. Our management uses non-GAAP measures to evaluate the performance of our business and to compensate employees. This information facilitates our management's internal comparisons to our historical operating results as well as to the operating results of our competitors. Since management finds this measure to be useful, we believe that our investors can benefit by evaluating both our non-GAAP and our GAAP results.

    Our management recognizes that items such as amortization of intangibles can have a material impact on our net income. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core operating business of the company.

    Readers are reminded that non-GAAP measures are merely a supplement to, and not a replacement for, or superior to our financial measures prepared according to GAAP. They should be evaluated in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.


    '/>"/>

    SOURCE Mesa Laboratories, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    2. Spherix Reports Second Quarter Earnings
    3. Tapestry Reports Second Quarter 2007 Results
    4. Callisto Reports on Second-Quarter 2007 Milestones
    5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    9. Biopure Reports on Meeting with the FDA
    10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
    11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
    (Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
    (Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
    Breaking Medicine Technology:
    (Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
    (Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
    (Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
    (Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
    (Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
    Breaking Medicine News(10 mins):